First comprehensive characterization of a Mycolicibacterium clinical isolate from sputum: antibiotic susceptibility, biochemical profile, and genomic features
Abstract
A putative novel rapidly growing Mycolicibacterium , designated Mycolicibacterium sp. strain NIID-NTM18-2, was first isolated in China from the sputum of a 60-year-old man suspected of lung cancer. Whole-genome sequencing (WGS) revealed an average nucleotide identity (ANI) of 99.7% between this strain and strain NIID-NTM18 previously isolated from a cardiac implantable electronic device in Japan, while showing only 88.27% ANI to its closest type strain, Mycolicibacterium litorale , suggesting that NIID-NTM18-2 and NIID-NTM18 may represent a novel species within the genus Mycolicibacterium . This is the first reported isolation of this species from sputum; furthermore, substantial genomic differences were observed between the two isolates. Additionally, we provide the first description of its fatty acid profile, biochemical reactions, and antibiotic susceptibility patterns. This comprehensive dataset provides critical evidence for accurate taxonomic classification, enhances epidemiological surveillance, and informs potential clinical management strategies.